| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11096913 | IBSA | High-stability packaged solutions of T4 thyroid hormone |
Feb, 2037
(12 years from now) | |
| US10537538 | IBSA | High-stability packaged solutions of T4 thyroid hormone |
Feb, 2037
(12 years from now) | |
| US11241382 | IBSA | Administration regimen of compositions of T4 thyroid hormone with high oral absorption |
Sep, 2039
(15 years from now) | |
Tirosint-Sol is owned by Ibsa.
Tirosint-Sol contains Levothyroxine Sodium.
Tirosint-Sol has a total of 3 drug patents out of which 0 drug patents have expired.
Tirosint-Sol was authorised for market use on 15 December, 2016.
Tirosint-Sol is available in solution;oral dosage forms.
Tirosint-Sol can be used as treatment of pituitary thyrotropin suppression by oral administration of l-thyroxine to a patient on an empty stomach 15 minutes before breakfast.
The generics of Tirosint-Sol are possible to be released after 17 September, 2039.
Drugs and Companies using LEVOTHYROXINE SODIUM ingredient
Market Authorisation Date: 15 December, 2016
Treatment: Treatment of pituitary thyrotropin suppression by oral administration of l-thyroxine to a patient on an empty stomach 15 minutes before breakfast
Dosage: SOLUTION;ORAL
TIROSINT-SOL family patents
